Sign Out
Pharmacology: Pharmacodynamics: Increased the sensitivity of the calcium-sensing receptor on the parathyroid gland thereby, concomitantly lowering parathyroid hormone (PTH), serum calcium, and serum phosphorus levels, preventing progressive bone disease and adverse events associated with mineral metabolism disorders.
Pharmacokinetics: Distribution: Vd: ~ 1,000 L.
Protein binding: ~ 93% to 97%.
Metabolism: Hepatic (extensive) via CYP3A4, 2D6, 1A2; forms inactive metabolites.
Half-life elimination: Terminal: 30 to 40 hours; moderate hepatic impairment: 65 hours; severe hepatic impairment: 84 hours.
Time to peak, Plasma: ~ 2 to 6 hours; increased with food.
Excretion: Urine ~ 80% (as metabolites); feces~ 15%.
Continue with Google